Search

Displaying results 4851 - 4860 of 8700 in total
  1. Drug

    ADC4022

    go.drugbank.com/drugs/DB05195
    Investigational

    ADC4022 is an investigational medicine for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and severe asthma.

  2. Drug

    3-hydroxyanthranilic acid

    go.drugbank.com/drugs/DB03644
    Experimental

    An oxidation product of tryptophan metabolism. It may be a free radical scavenger and a carcinogen.

  3. Drug

    KC706

    go.drugbank.com/drugs/DB05157
    Investigational

    KC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase.

  4. Drug

    LIC-477

    go.drugbank.com/drugs/DB05363
    Experimental

    LIC-477is indicated to be suitable for the treatment of psychosomatic disturbances, epilepsy, trigeminal neuralgia and cerebral spasticity.

  5. Drug

    Arundic acid

    go.drugbank.com/drugs/DB05343
    Investigational

    Arundic acid has been investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).

  6. Drug

    Binodenoson

    go.drugbank.com/drugs/DB04853
    Investigational

    Binodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A<sub>2A</sub> receptor.

    Categories: Purinergic P1 Receptor Agonists
  7. Drug

    Interferon alfa-n3

    go.drugbank.com/drugs/DB00018
    Approved

    Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  8. Drug

    QS-21

    go.drugbank.com/drugs/DB05400
    Investigational

    QS-21 is an investigational adjuvant, which is a substance added to vaccines and other immunotherapies that is designed to enhance the body’s immune response to the antigen contained within the treatment

  9. Drug

    G207

    go.drugbank.com/drugs/DB05827
    Investigational

    G207 is cancer-killing viruses, so-called oncolytic viruses, for the treatment of various forms of cancer developed by MediGene AG.

  10. Drug

    LetibotulinumtoxinA

    go.drugbank.com/drugs/DB16820
    Approved

    [L42335] It was approved for use in the treatment of glabellar lines in Canada in June 2022[L42330,L42335] and in the US in March 2024.[L50291,L50296] … [A249920] It was subsequently approved by the FDA in 1992 for use in aesthetic procedures and has since become one of the most popular cosmetic procedures worldwide.